1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048


Delayed Swiss Exchange  -  05/20 11:30:37 am EDT
319.70 CHF   +0.88%
05/20Biocon Biologics and Viatris Launch Abevmy (bBevacizumab), Their Third Oncology Biosimilar, in Canada
05/20Cancer coalition aims to boost access to medicines in poorer countries
05/19ROCHE HOLDINGS AG : Credit Suisse reiterates its Neutral rating
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Roche believes cancer drug setback not a fatal blow to growth prospects

05/12/2022 | 10:15am EDT
FILE PHOTO: Roche Chairman Christoph Franz speaks to media in Basel

ZURICH, May 12 (Reuters) - Roche Holding AG has enough in its drug development pipeline to make up for the recent setback of its keenly-watched experimental cancer drug, Chairman Christoph Franz said on Thursday.

On Wednesday, the Swiss drugmaker's stock had its worst day since March 2020, after an interim analysis of an ongoing clinical trial showed its drug, tiragolumab, failed to meaningfully slow disease progression in patients with the most common form of lung cancer.

It was the second tiragolumab trial that fell short of expectations.

"There are always setbacks, we are used to that. We of course had growth expectations, which have for now been disappointed," said Franz, who heads the family-controlled company's board of directors.

The advantage of a company the size of Roche is that there are several late-stage trials that the company is also banking on to enrich its growth prospects, he suggested.

One particularly high-risk, high reward prospect in the company's arsenal is its experimental Alzheimer's drug, gantenerumab. Franz sought to temper expectations that trial results for gantenerumab, expected later this year, would make up for this week's disappointment.

The field targeting the memory-robbing disease - which affects millions of people globally - is littered with high profile failures.

Adoption of the first new Alzheimer's treatment in nearly 20 years, made by rival U.S. drugmaker Biogen Inc, spectacularly underwhelmed after the U.S. health regulator green lit the treatment without clear evidence of patient benefit, driven in part by the lack of options for the fatal mind-wasting disease.

"Everyone knows Alzheimer's research is a very risky type of research," Franz said.

Roche is hoping that its blood cancer drug, glofitamab, will bolster growth prospects alongside a growing demand for its other prime focus - diagnostics.

The world's biggest cancer drug maker is poised to pioneer the use of mass spectrometry in healthcare diagnostics, a method so far only used in research.

"Many of our competitors probably balk at the investment," Franz said.

Others investments can come in the form of deals. Franz suggested the company remains open to acquiring assets to promote growth.

Drugmakers often go shopping to reinvigorate their pipelines, and the recent downturn in the biotech sector means M&A targets that were once considered too expensive are now within reach.

Roche has about $16 billion in its coffers, according to a note from Jefferies analysts earlier this month.

"Over the last few years we were confronted with market prices that did not leave any room for commercial viability," Franz said of acquiring drugs from others through deals or acquisitions.

"If prices are now becoming more attractive, that could also affect our interest."

(Reporting by Ludwig Burger and additional reporting by Natalie Grover in London; Editing by David Evans, Lisa Shumaker and Bill Berkrot)

© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
BIOGEN INC. 3.40% 199.65 Delayed Quote.-16.78%
ROCHE HOLDING AG 0.88% 319.7 Delayed Quote.-15.67%
All news about ROCHE HOLDING AG
05/20Biocon Biologics and Viatris Launch Abevmy (bBevacizumab), Their Third Oncology Biosimi..
05/20Cancer coalition aims to boost access to medicines in poorer countries
05/19ROCHE HOLDINGS AG : Credit Suisse reiterates its Neutral rating
05/18Judgement On The First Drug Patent Linkage Lawsuit In China Is Issued
05/17AlphaValue/Baader Europe Lifts Price Target on Roche, Maintains Add Recommendation
05/16TRANSCRIPT : Roche Holding AG - Special Call
05/13PUMP / DUMP #31 : The week's gainers and losers
05/13ROCHE HOLDINGS AG : Reduced to Neutral by Jefferies
05/12Roche believes cancer drug setback not a fatal blow to growth prospects
05/12ROCHE HOLDINGS AG : Gets a Neutral rating from Morgan Stanley
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Sales 2022 64 028 M 65 632 M 65 632 M
Net income 2022 14 979 M 15 354 M 15 354 M
Net Debt 2022 11 180 M 11 460 M 11 460 M
P/E ratio 2022 17,1x
Yield 2022 3,04%
Capitalization 260 B 267 B 267 B
EV / Sales 2022 4,24x
EV / Sales 2023 4,06x
Nbr of Employees 100 920
Free-Float 82,4%
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 319,70 CHF
Average target price 396,90 CHF
Spread / Average Target 24,1%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Officer
Christoph Franz Chairman
Levi A. Garraway Chief Medical Officer
Pascale Schmidt Chief Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG-15.67%266 707
JOHNSON & JOHNSON1.68%465 705
PFIZER, INC.-11.14%294 404
ABBVIE INC.11.53%266 851
NOVO NORDISK A/S3.58%245 099